Literature DB >> 18653744

Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether.

Chitra Sridar1, Ute M Kent, Kate Noon, Alecia McCall, Bill Alworth, Maryam Foroozesh, Paul F Hollenberg.   

Abstract

The abilities of 7-coumarin propargyl ether (CPE) and 7-(4-trifluoromethyl)coumarin propargyl ether (TFCPE) to act as mechanism-based inactivators of P450 3A4 and 3A5 in the reconstituted system have been investigated using 7-benzyloxy-4-(trifluoromethyl)coumarin (BFC) and testosterone as probes. CPE inhibited the BFC O-debenzylation activity of P450 3A4 in a time-, concentration-, and NADPH-dependent manner characteristic of a mechanism-based inactivator with a half-maximal inactivation (K(I)) of 112 microM, a maximal rate of inactivation (k(inact)) of 0.05 min(-1), and a t(1/2) of 13.9 min. Similarly, TFCPE inhibited the BFC O-debenzylation activity of P450 3A4 in a time-, concentration-, and NADPH-dependent manner with a K(I) of 14 microM, a k(inact) of 0.04 min(-1), and a t(1/2) of 16.5 min. Parallel losses of P450 3A4 enzymatic activity and heme were observed with both compounds as measured by high-performance liquid chromatography and reduced CO spectra. Interestingly, neither compound inhibited the BFC O-debenzylation activity of P450 3A5. Reactive intermediates of CPE and TFCPE formed by P450 3A4 were trapped with glutathione, and the resulting adducts were identified using tandem mass spectral analysis. Metabolism studies using TFCPE resulted in the identification of a single metabolite that is formed by P450 3A4 but not by P450 3A5 and that may play a role in the mechanism-based inactivation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18653744      PMCID: PMC2736802          DOI: 10.1124/dmd.108.021493

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  37 in total

Review 1.  Pharmacogenomics: translating functional genomics into rational therapeutics.

Authors:  W E Evans; M V Relling
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

2.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

3.  Metabolism of coumarin by human P450s: a molecular modelling study.

Authors:  David F V Lewis; Yuko Ito; Brian G Lake
Journal:  Toxicol In Vitro       Date:  2005-09-12       Impact factor: 3.500

4.  Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.

Authors:  R W Wang; D J Newton; N Liu; W M Atkins; A Y Lu
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

5.  Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.

Authors:  Landry K Kamdem; Frank Streit; Ulrich M Zanger; Jürgen Brockmöller; Michael Oellerich; Victor W Armstrong; Leszek Wojnowski
Journal:  Clin Chem       Date:  2005-06-10       Impact factor: 8.327

6.  Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.

Authors:  Ying-Hong Wang; David R Jones; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2005-02-02       Impact factor: 3.922

7.  Identification of the human liver microsomal cytochrome P450s involved in the metabolism of N-nitrosodi-n-propylamine.

Authors:  J F Teiber; P F Hollenberg
Journal:  Carcinogenesis       Date:  2000-08       Impact factor: 4.944

Review 8.  Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment.

Authors:  B G Lake
Journal:  Food Chem Toxicol       Date:  1999-04       Impact factor: 6.023

9.  Selective metabolism of vincristine in vitro by CYP3A5.

Authors:  Jennifer B Dennison; Palaniappan Kulanthaivel; Robert J Barbuch; Jamie L Renbarger; William J Ehlhardt; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2006-05-05       Impact factor: 3.922

10.  Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation.

Authors:  Brian R Baer; Larry C Wienkers; Dan A Rock
Journal:  Chem Res Toxicol       Date:  2007-05-12       Impact factor: 3.739

View more
  6 in total

1.  QSAR models of cytochrome P450 enzyme 1A2 inhibitors using CoMFA, CoMSIA and HQSAR.

Authors:  J Sridhar; M Foroozesh; C L Klein Stevens
Journal:  SAR QSAR Environ Res       Date:  2011-10-17       Impact factor: 3.000

2.  7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2.

Authors:  Jiawang Liu; Thong T Nguyen; Patrick S Dupart; Jayalakshmi Sridhar; Xiaoyi Zhang; Naijue Zhu; Cheryl L Klein Stevens; Maryam Foroozesh
Journal:  Chem Res Toxicol       Date:  2012-04-10       Impact factor: 3.739

Review 3.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

4.  Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein.

Authors:  Hsia-Lien Lin; Haoming Zhang; Kathleen R Noon; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2009-08-21       Impact factor: 4.030

5.  Development of flavone propargyl ethers as potent and selective inhibitors of cytochrome P450 enzymes 1A1 and 1A2.

Authors:  Jayalakshmi Sridhar; Jamie Ellis; Patrick Dupart; Jiawang Liu; Cheryl L Stevens; Maryam Foroozesh
Journal:  Drug Metab Lett       Date:  2012

6.  Hibiscus sabdariffa Extract Protects HaCaT Cells against Phenanthrene-Induced Toxicity through the Regulation of Constitutive Androstane Receptor/Pregnane X Receptor Pathway.

Authors:  Dicson Sheeja Malar; Mani Iyer Prasanth; Kanika Verma; Anchalee Prasansuklab; Tewin Tencomnao
Journal:  Nutrients       Date:  2022-09-16       Impact factor: 6.706

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.